Ouro Fino Saúde Animal Participações S.A. (BVMF:OFSA3)
Brazil · Delayed Price · Currency is BRL | Market Cap | 1.34B +12.4% |
| Revenue (ttm) | 1.37B +26.7% |
| Net Income | 236.09M +80.4% |
| EPS | 4.39 +80.4% |
| Shares Out | 53.77M |
| PE Ratio | 5.69 |
| Forward PE | n/a |
| Dividend | 1.29 (5.22%) |
| Ex-Dividend Date | Apr 17, 2026 |
| Volume | 700 |
| Open | 24.90 |
| Previous Close | 24.98 |
| Day's Range | 24.90 - 25.00 |
| 52-Week Range | 20.90 - 34.69 |
| Beta | 0.29 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 6, 2026 |
About BVMF:OFSA3
Ouro Fino Saúde Animal Participações S.A., together with its subsidiaries, engages in the development, production, and sale of veterinary drugs, vaccines, and other products for production and companion animals primarily in Brazil. The company operates through three segments: Production Animals; Companion Animals; and International Operations. It manufactures and trades in medicines, including anti-inflammatories, antibiotics, anticoccidials, antimastitics, ectoparasiticides, endectocides, endoparasiticides, hemoparasiticides, inoculants, thera... [Read more]
Full Company ProfileFinancial Performance
In 2025, BVMF:OFSA3's revenue was 1.22 billion, an increase of 19.54% compared to the previous year's 1.02 billion. Earnings were 222.31 million, an increase of 65.50%.
Financial StatementsNews
Ouro Fino Saúde Animal Participações Transcript: Transcript
Q2 saw nearly 20% revenue growth and 26.5% EBITDA growth, led by new product launches and strong livestock and international performance. Pet segment growth was modest due to macroeconomic pressures, but outlook for the second half remains positive.
Ouro Fino Saúde Animal Participações Transcript: Transcript
Adjusted for the absence of the Foot-and-Mouth Disease campaign, revenue and EBITDA grew strongly year-over-year, with significant margin improvements and robust cash flow. New product launches and cost discipline supported growth in both production animals and pets, while international operations faced mixed results.
Ouro Fino Saúde Animal Participações Transcript: Transcript
Q3 2024 saw double-digit revenue and EBITDA growth, margin expansion, and strong cash flow, driven by new product launches and operational efficiency. Despite logistics and climate challenges, both production animal and pet segments delivered robust results, with a positive outlook for 2025.
Ouro Fino Saúde Animal Participações Transcript: Transcript
Q4 2025 saw revenue up 23.2% and net income up 17.2% year-over-year, driven by strong product launches, reduced expenses, and international expansion. Guidance for 2026 targets continued growth above prior year, with a focus on Latin America and biologics.
Ouro Fino Saúde Animal Participações Transcript: Transcript
Q1 2026 saw over 30% revenue growth, margin expansion, and strong cash generation, driven by new product launches and operational efficiency. Production and companion animal segments both grew, with international operations gaining relevance. Dividend payouts increased alongside continued investment.
Ouro Fino Saúde Animal Participações Transcript: Transcript
Revenue grew 14% year-over-year to BRL 1 billion, with all business units contributing and EBITDA margin rising to 21.6%. Seven new products were launched, cash generation was strong, and leverage was reduced, supporting continued investment and international expansion.
Ouro Fino Saúde Animal Participações Transcript: Transcript
Ouro Fino Saúde Animal Participações Transcript: Transcript
Ouro Fino Saúde Animal Participações Transcript: Transcript
Ouro Fino Saúde Animal Participações Transcript: Transcript
Ouro Fino Saúde Animal Participações Transcript: Transcript
Revenue and EBITDA grew 26% and 30% year-over-year, driven by innovative product launches and strong segment performance. Robust liquidity, long-term debt structure, and continued R&D investment support future growth.
Ouro Fino Saúde Animal Participações Transcript: Transcript
Ouro Fino Saúde Animal Participações Transcript: Transcript
Q1 2025 saw 6.3% revenue growth and a gross margin of 48.5%, with strong gains in pet and international segments. New product launches and robust cash flow support a positive outlook, though higher SG&A and R&D investments may pressure margins.
Ouro Fino Saúde Animal Participações Earnings Call Transcript: Q2 2026
Net revenue grew over 30% year-over-year, with strong gains in both production and companion animal segments. EBITDA and net income margins expanded, supported by innovation and international growth, despite some one-time impacts from project suspensions.
Ouro Fino Saúde Animal Participações Earnings release: Q2 2026
Ouro Fino Saúde Animal Participações released its Q2 2026 earnings on August 7, 2026, summarizing the period's financial results.
Ouro Fino Saúde Animal Participações Slides: Company presentation
Ouro Fino Saúde Animal Participações has posted slides in relation to its latest quarterly earnings report, which was published on March 1, 2026.